November 2020 – Headquartered in Cambridge, MA Seres Therapeutics is a late-clinical stage biotechnology company working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.

October 2020 — Headquartered in South San Francisco, CA, Atreca focuses on the immune response of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes, enabling us to discover and develop novel immunotherapies, including those in our lead programs in Oncology.

October 2020 — With offices in Waltham, MA, Adagio's mission is to provide an effective long-term solution for the global Coronavirus challenge.

September 2020 — Located in Austin, TX, Molecular Templates is focused on the discovery, development and commercialization of next generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancer.

August 2020 — With offices in Cambridge, MA, Celsius' mission is to develop life-saving medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning.

February 2020 — With offices in Cambridge, MA, Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.

January 2020 — With US offices in San Diego and South San Francisco, Shouti Pharmaceuticals will be using R&D Logic's R&D Time to manage and prioritize portfolio resources.

December 2019 — With offices in Ottawa and New York City, Turnstone Biologics' mission is to deliver breakthrough viral immunotherapies to improve survival for patients with cancer.

June 2019 — Located in San Diego, CA, Turning Point Therapeutics has created a new generation of therapies that are different from the conventional kinase inhibitors. Their compact molecules are potentially more potent and selective medicines that also hold promise to prevent and overcome resistance.

March 2019 — Located in Cambridge, MA, Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer.

August 2018 — Located in Vancouver, BC, Ondine is focused on the development and commercialization of their patented light activated technology, photodisinfection. Photodisinfection provides rapid antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.

July 2018 — Located in Cambridge, MA, RA Pharma is a clinical-stage biopharmaceutical company using a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system.

June 2018 — Located in Richmond, CA, Sangamo Therapeutics believes, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases.

March 2018 — Located in Redwood City, CA ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors.

October 2017 — Founded in 1994, and located in South San Francisco, CA, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.